<?xml version="1.0" encoding="UTF-8"?>
<p>Groups of five female BALB/c mice (~8 weeks old) were immunized intramuscularly at day 0 with either 10
 <sup>10</sup> vp or 10
 <sup>8</sup> vp of Ad5-Mosaic, Ad5-A/PR/8/34, Ad5-Pdm09, control PBS, or 600 ng of HA (approximately 30× a human dose) from the 2018–2019 Fluzone vaccine generously donated from Bryan Health, Lincoln, NE, USA. At three weeks post-immunization, all mice were challenged intranasally with 100 MLD
 <sub>50</sub> of A/PR/8/34 and A/FM/1/47 or 10
 <sup>3.6</sup> TCID
 <sub>50</sub> equivalents of A/Nanchang/1/99. All mice were monitored daily for weight loss and survival. Mice were humanely euthanized at 25% weight loss.
</p>
